Schedule 13G ownership disclosure
C4 Therapeutics Inc
Common Stock, par value $0.0001 per share · CUSIP: 12529R107
Event date: 2025-10-17
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Point72 Asset Management, L.P.
Shares: 22,647,647.00 · Class: 9.9%
- Point72 Capital Advisors, Inc.
Shares: 22,647,647.00 · Class: 9.9%
- Steven A. Cohen
Shares: 22,647,647.00 · Class: 9.9%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000902664-25-004471
- Form type
- SCHEDULE 13G
- Filer
- C4 Therapeutics, Inc.
- CIK
- CIK 1662579
- Filed
- Oct 20, 2025
- Reporting period
- Oct 17, 2025
- Description
- Schedule 13G beneficial ownership